search
Back to results

Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia

Primary Purpose

Hypercholesterolemia

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Plant stanol esters
Sponsored by
Gerencia de Atención Primaria, Albacete
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypercholesterolemia focused on measuring Hypercholesterolemia, Lipids, Cardiovascular disease, Risks factors, Primary Care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects diagnosed with limit hypercholesterolaemia (total cholesterol 200-249 mg/dl) or defined hypercholesterolaemia (total cholesterol equal to or above 250 mg/dl) who have LDL-cholesterol levels equal to or above 130 mg/dl
  • Subjects aged 18 years or over attending the participating health centres
  • Subjects who give their consent to participate after being informed of the study objectives

Exclusion Criteria:

  • Known hypersensitivity to sterol esters or to the other components of the food that contains them (liquid yoghurt)
  • Contraindication for treatment with sterol esters or any of the components of the food
  • Physical disability that hinders collaboration
  • Significant chronic organic or psychiatric disease
  • Not obtaining informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Liquid yoghurt with plant stanol esters

    Yoghurt without plant stanol esters

    Arm Description

    Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.

    Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.

    Outcomes

    Primary Outcome Measures

    Change in lipid profile
    Lipid levels will be measured in both plasma and capillary blood at the initial visit. The validity of the capillary blood lipid levels can be checked with the Cardiochek analyser (by total cholesterol, HDL-cholesterol and triglyceride strips, and subsequent calculation of LDL-cholesterol using the Friedewald formula). The measurements at 3, 12 and 24 months will be in plasma. At 1, 6 and 18 months they will only be in capillary blood.

    Secondary Outcome Measures

    Change in cardiovascular risk
    SCORE and REGICOR tables will be used for the evaluation.
    Adherence to the dairy product (liquid yoghurt)
    By self-report and Morisky-Green scale, which determines the degree of coincidence between the patient's behaviour and the doctor's advice (a non-complier is one who answers one of the four questions of the scale inappropriately).
    Adverse events
    Considered as any undesirable event in any patient included in the study, even though it does not have a causal relation with the product. Known adverse events of phytosterols in the diet at the proposed doses: occasionally mild digestive alterations.
    Adherence to the dietary recommendations
    5-point Likert scale
    Frequency of food intake
    Using the CDC-FFQ questionnaire, validated in Spain (Aguirre, 2008) considered appropriate to classify the subjects according to their intake of food and nutrients.
    Occurrence of cardiovascular events
    Ischaemic heart disease, atherothrombotic cerebrovascular disease, heart failure and peripheral artery disease. -Weight, height, body mass index (BMI): classification of subjects according to degree of obesity.
    Weight, height, body mass index (BMI)
    Classification of subjects according to degree of obesity.
    Physical activity
    Amount of aerobic exercise ("active" if performs aerobic exercise for 30 minutes or more, three or more times a week, "partially active" if exercises with less frequency and for less time that this and "inactive" when does not perform any type of exercise).
    Smoking habit
    Considered smoker if answers yes to the question "do you smoke?"
    Systolic and diastolic blood pressure (two measurements):
    The result will be the mean of the two measurements.
    Health problems
    (WONCA ICPC-2)
    Lipid-lowering pharmacological treatment.
    Whether taking lipid-lowering pharmacological treatment.
    Socio-demographic data
    Age, gender, marital status, educational level and social class based on occupation (National Classification of Occupations).

    Full Information

    First Posted
    July 28, 2011
    Last Updated
    July 28, 2011
    Sponsor
    Gerencia de Atención Primaria, Albacete
    Collaborators
    Fundación para la Investigación Sanitaria en Castilla-La Mancha (FISCAM), Castilla-La Mancha Health Research Foundation.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01406106
    Brief Title
    Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia
    Official Title
    EFFECT OF PLANT STEROLS ON THE LIPID PROFILE OF PATIENTS WITH HYPERCHOLESTEROLAEMIA. RANDOMISED, EXPERIMENTAL STUDY
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2011
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2010 (undefined)
    Primary Completion Date
    December 2011 (Anticipated)
    Study Completion Date
    December 2012 (Anticipated)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Gerencia de Atención Primaria, Albacete
    Collaborators
    Fundación para la Investigación Sanitaria en Castilla-La Mancha (FISCAM), Castilla-La Mancha Health Research Foundation.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Background information Studies have been conducted on supplementing the daily diet with plant sterol ester-enriched milk derivatives in order to reduce LDL-cholesterol levels and, consequently, cardiovascular risk. However, clinical practice guidelines on hypercholesterolaemia state that there is not sufficient evidence to recommend their use in subjects with hypercholesterolaemia. The null hypothesis establishes that there is no relationship between the decrease in blood LDL-cholesterol levels and the consumption of stanol ester enriched liquid yoghurt. The alternative hypothesis establishes a relationship between such consumption and the incidence of the primary variable. The main objective of this study is to determine the efficacy of the intake of 2 g of plant sterol esters a day in lowering LDL-cholesterol levels in patients diagnosed with hypercholesterolaemia. The specific objectives are: 1) to quantify the efficacy of the daily intake of plant sterol esters in lowering LDL-cholesterol, total cholesterol and cardiovascular risk in patients with hypercholesterolaemia; 2) to evaluate the occurrence of adverse effects of the daily intake of plant sterol esters; 3) to identify the factors that determine a greater reduction in lipid levels in subjects receiving plant sterol ester supplements. Study design Randomised, double-blind, placebo controlled experimental trial carried out at family doctors' surgeries at three health centres in the Health Area of Albacete (Spain). The study subjects will be adults diagnosed with "limit" or "defined" hypercholesterolaemia and who have LDL cholesterol levels of 130 mg/dl or over. A dairy product in the form of liquid yoghurt containing 2 g of plant sterol ester per container will be administered daily after the main meal, for a period of 24 months. The control group will receive a daily unit of yogurt not supplemented with plant sterol esters that has a similar appearance to the enriched yoghurt. The primary variable is the change in lipid profile at 1, 3, 6, 12, 18 and 24 months. The secondary variables are: change in cardiovascular risk, adherence to the dairy product, adverse effects, adherence to dietary recommendations, frequency of food consumption, basic physical examination data, health problems, lipid-lowering medication, physical activity, smoking habits and socio-demographic variables.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypercholesterolemia
    Keywords
    Hypercholesterolemia, Lipids, Cardiovascular disease, Risks factors, Primary Care

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    182 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Liquid yoghurt with plant stanol esters
    Arm Type
    Experimental
    Arm Description
    Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
    Arm Title
    Yoghurt without plant stanol esters
    Arm Type
    Placebo Comparator
    Arm Description
    Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Plant stanol esters
    Intervention Description
    The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
    Primary Outcome Measure Information:
    Title
    Change in lipid profile
    Description
    Lipid levels will be measured in both plasma and capillary blood at the initial visit. The validity of the capillary blood lipid levels can be checked with the Cardiochek analyser (by total cholesterol, HDL-cholesterol and triglyceride strips, and subsequent calculation of LDL-cholesterol using the Friedewald formula). The measurements at 3, 12 and 24 months will be in plasma. At 1, 6 and 18 months they will only be in capillary blood.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Secondary Outcome Measure Information:
    Title
    Change in cardiovascular risk
    Description
    SCORE and REGICOR tables will be used for the evaluation.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Adherence to the dairy product (liquid yoghurt)
    Description
    By self-report and Morisky-Green scale, which determines the degree of coincidence between the patient's behaviour and the doctor's advice (a non-complier is one who answers one of the four questions of the scale inappropriately).
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Adverse events
    Description
    Considered as any undesirable event in any patient included in the study, even though it does not have a causal relation with the product. Known adverse events of phytosterols in the diet at the proposed doses: occasionally mild digestive alterations.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Adherence to the dietary recommendations
    Description
    5-point Likert scale
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Frequency of food intake
    Description
    Using the CDC-FFQ questionnaire, validated in Spain (Aguirre, 2008) considered appropriate to classify the subjects according to their intake of food and nutrients.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Occurrence of cardiovascular events
    Description
    Ischaemic heart disease, atherothrombotic cerebrovascular disease, heart failure and peripheral artery disease. -Weight, height, body mass index (BMI): classification of subjects according to degree of obesity.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Weight, height, body mass index (BMI)
    Description
    Classification of subjects according to degree of obesity.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Physical activity
    Description
    Amount of aerobic exercise ("active" if performs aerobic exercise for 30 minutes or more, three or more times a week, "partially active" if exercises with less frequency and for less time that this and "inactive" when does not perform any type of exercise).
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Smoking habit
    Description
    Considered smoker if answers yes to the question "do you smoke?"
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Systolic and diastolic blood pressure (two measurements):
    Description
    The result will be the mean of the two measurements.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Health problems
    Description
    (WONCA ICPC-2)
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Lipid-lowering pharmacological treatment.
    Description
    Whether taking lipid-lowering pharmacological treatment.
    Time Frame
    At 1, 3, 6, 12, 18 and 24 months
    Title
    Socio-demographic data
    Description
    Age, gender, marital status, educational level and social class based on occupation (National Classification of Occupations).
    Time Frame
    Initial visit

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subjects diagnosed with limit hypercholesterolaemia (total cholesterol 200-249 mg/dl) or defined hypercholesterolaemia (total cholesterol equal to or above 250 mg/dl) who have LDL-cholesterol levels equal to or above 130 mg/dl Subjects aged 18 years or over attending the participating health centres Subjects who give their consent to participate after being informed of the study objectives Exclusion Criteria: Known hypersensitivity to sterol esters or to the other components of the food that contains them (liquid yoghurt) Contraindication for treatment with sterol esters or any of the components of the food Physical disability that hinders collaboration Significant chronic organic or psychiatric disease Not obtaining informed consent
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ignacio Párraga, PhD
    Organizational Affiliation
    Research Unit. Primary Care Head Office of Albacete
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Jesús López-Torres, PhD
    Organizational Affiliation
    Research Unit. Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Fernando Andrés, Bachelor of Computer Sciences
    Organizational Affiliation
    Research Unit. Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Beatriz Navarro, PhD
    Organizational Affiliation
    Research Unit. Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    José María Del Campo, PhD
    Organizational Affiliation
    Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Mercedes García-Reyes, PhD
    Organizational Affiliation
    Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    María Pilar Galdón, PhD
    Organizational Affiliation
    Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Ángeles Lloret, Bachelor of Pharmacy
    Organizational Affiliation
    Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Juan Carlos Precioso, Bachelor of Medicine
    Organizational Affiliation
    Primary Care Head Office of Albacete.
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Joseba Rabanales, Bachelor of Nursing
    Organizational Affiliation
    Research Unit. Primary Care Head Office of Albacete.
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    15871776
    Citation
    Medrano MJ, Cerrato E, Boix R, Delgado-Rodriguez M. [Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies]. Med Clin (Barc). 2005 Apr 30;124(16):606-12. doi: 10.1157/13074389. Spanish.
    Results Reference
    background
    PubMed Identifier
    11141438
    Citation
    Gutierrez Fuentes JA, Gomez-Jerique J, Gomez De La Camara A, Angel Rubio M, Garcia Hernandez A, Aristegui I; Diet and Cardiovascular Risk in Spain Study (DRECE II). [Diet and cardiovascular risk in Spain. Description of the evolution of cardiovascular prolile]. Med Clin (Barc). 2000 Dec 2;115(19):726-9. Spanish.
    Results Reference
    background
    PubMed Identifier
    8043072
    Citation
    Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367-72. doi: 10.1136/bmj.308.6925.367.
    Results Reference
    background
    PubMed Identifier
    12089098
    Citation
    Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002 Jun 29;324(7353):1570-6. doi: 10.1136/bmj.324.7353.1570. No abstract available.
    Results Reference
    background
    PubMed Identifier
    7368981
    Citation
    Keys A. Coronary heart disease, serum cholesterol, and the diet. Acta Med Scand. 1980;207(3):153-60. doi: 10.1111/j.0954-6820.1980.tb09697.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    16214597
    Citation
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27. Erratum In: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.
    Results Reference
    background
    PubMed Identifier
    12450892
    Citation
    McCullough ML, Feskanich D, Stampfer MJ, Giovannucci EL, Rimm EB, Hu FB, Spiegelman D, Hunter DJ, Colditz GA, Willett WC. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr. 2002 Dec;76(6):1261-71. doi: 10.1093/ajcn/76.6.1261.
    Results Reference
    background
    PubMed Identifier
    12396226
    Citation
    Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62(16):2333-47. doi: 10.2165/00003495-200262160-00002.
    Results Reference
    background
    PubMed Identifier
    15699225
    Citation
    Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Trautwein EA, Lapsley KG, Josse RG, Leiter LA, Singer W, Connelly PW. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr. 2005 Feb;81(2):380-7. doi: 10.1093/ajcn.81.2.380.
    Results Reference
    background
    PubMed Identifier
    9849358
    Citation
    Bellisle F, Blundell JE, Dye L, Fantino M, Fern E, Fletcher RJ, Lambert J, Roberfroid M, Specter S, Westenhofer J, Westerterp-Plantenga MS. Functional food science and behaviour and psychological functions. Br J Nutr. 1998 Aug;80 Suppl 1:S173-93. doi: 10.1079/bjn19980109.
    Results Reference
    background
    PubMed Identifier
    11412648
    Citation
    Ros E. [Introduction to functional food]. Med Clin (Barc). 2001 May 5;116(16):617-9. doi: 10.1016/s0025-7753(01)71924-0. No abstract available. Spanish.
    Results Reference
    background
    PubMed Identifier
    12852326
    Citation
    Silveira Rodriguez MB, Monereo Megias S, Molina Baena B. [Functional nutrition and optimal nutrition. Near or far?]. Rev Esp Salud Publica. 2003 May-Jun;77(3):317-31. Spanish.
    Results Reference
    background
    PubMed Identifier
    11834929
    Citation
    Cater NB. Plant stanol ester: review of cholesterol-lowering efficacy and implications for coronary heart disease risk reduction. Prev Cardiol. 2000 Summer;3(3):121-130. doi: 10.1111/j.1520-037x.2000.80370.x.
    Results Reference
    background
    PubMed Identifier
    10736328
    Citation
    Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000 Apr;130(4):767-76. doi: 10.1093/jn/130.4.767.
    Results Reference
    background
    PubMed Identifier
    7566021
    Citation
    Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995 Nov 16;333(20):1308-12. doi: 10.1056/NEJM199511163332002.
    Results Reference
    background
    PubMed Identifier
    10799370
    Citation
    Miettinen TA, Vuoristo M, Nissinen M, Jarvinen HJ, Gylling H. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr. 2000 May;71(5):1095-102. doi: 10.1093/ajcn/71.5.1095.
    Results Reference
    background
    PubMed Identifier
    15316827
    Citation
    Noakes M, Clifton PM, Doornbos AM, Trautwein EA. Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects. Eur J Nutr. 2005 Jun;44(4):214-22. doi: 10.1007/s00394-004-0513-z. Epub 2004 Aug 17.
    Results Reference
    background
    PubMed Identifier
    10867091
    Citation
    Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000 Jul 1;86(1):46-52. doi: 10.1016/s0002-9149(00)00976-0.
    Results Reference
    background
    PubMed Identifier
    11522112
    Citation
    Nigon F, Serfaty-Lacrosniere C, Beucler I, Chauvois D, Neveu C, Giral P, Chapman MJ, Bruckert E. Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: effect of fibrate treatment. Clin Chem Lab Med. 2001 Jul;39(7):634-40. doi: 10.1515/CCLM.2001.103.
    Results Reference
    background
    PubMed Identifier
    12498007
    Citation
    Gylling H, Miettinen TA. Combination therapy with statins. Curr Opin Investig Drugs. 2002 Sep;3(9):1318-23.
    Results Reference
    background
    PubMed Identifier
    12911045
    Citation
    Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R; Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003 Aug;78(8):965-78. doi: 10.4065/78.8.965.
    Results Reference
    background
    PubMed Identifier
    10731187
    Citation
    Law M. Plant sterol and stanol margarines and health. BMJ. 2000 Mar 25;320(7238):861-4. doi: 10.1136/bmj.320.7238.861. No abstract available.
    Results Reference
    background
    PubMed Identifier
    11755939
    Citation
    Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis. 2002 Jan;160(1):205-13. doi: 10.1016/s0021-9150(01)00562-7.
    Results Reference
    background
    PubMed Identifier
    15330272
    Citation
    O'Neill FH, Brynes A, Mandeno R, Rendell N, Taylor G, Seed M, Thompson GR. Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr Metab Cardiovasc Dis. 2004 Jun;14(3):133-42. doi: 10.1016/s0939-4753(04)80033-4.
    Results Reference
    background
    PubMed Identifier
    7072622
    Citation
    Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol absorption in man. Am J Clin Nutr. 1982 Apr;35(4):697-700. doi: 10.1093/ajcn/35.4.697.
    Results Reference
    background
    PubMed Identifier
    11002377
    Citation
    Plat J, van Onselen EN, van Heugten MM, Mensink RP. Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters. Eur J Clin Nutr. 2000 Sep;54(9):671-7. doi: 10.1038/sj.ejcn.1601071.
    Results Reference
    background
    PubMed Identifier
    11368702
    Citation
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available.
    Results Reference
    background
    PubMed Identifier
    11678485
    Citation
    Van Horn L, Ernst N. A summary of the science supporting the new National Cholesterol Education Program dietary recommendations: what dietitians should know. J Am Diet Assoc. 2001 Oct;101(10):1148-54. doi: 10.1016/s0002-8223(01)00283-8. No abstract available.
    Results Reference
    background
    PubMed Identifier
    11222485
    Citation
    Lichtenstein AH, Deckelbaum RJ. AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation. 2001 Feb 27;103(8):1177-9. doi: 10.1161/01.cir.103.8.1177.
    Results Reference
    background
    PubMed Identifier
    16785338
    Citation
    American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006 Jul 4;114(1):82-96. doi: 10.1161/CIRCULATIONAHA.106.176158. Epub 2006 Jun 19. Erratum In: Circulation. 2006 Dec 5;114(23):e629. Circulation. 2006 Jul 4;114(1):e27.
    Results Reference
    background
    PubMed Identifier
    15766477
    Citation
    Algorta Pineda J, Chinchetru Ranedo MJ, Aguirre Anda J, Francisco Terreros S. [Hypocholesteremic effectiveness of a yogurt containing plant stanol esters]. Rev Clin Esp. 2005 Feb;205(2):63-6. doi: 10.1157/13072497. Spanish.
    Results Reference
    background
    PubMed Identifier
    10341155
    Citation
    Slesinski RS, Turnbull D, Frankos VH, Wolterbeek AP, Waalkens-Berendsen DH. Developmental toxicity study of vegetable oil-derived stanol fatty acid esters. Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 1):227-33. doi: 10.1006/rtph.1999.1292.
    Results Reference
    background
    PubMed Identifier
    15164112
    Citation
    De Jong N, Pijpers L, Bleeker JK, Ocke MC. Potential intake of phytosterols/-stanols: results of a simulation study. Eur J Clin Nutr. 2004 Jun;58(6):907-19. doi: 10.1038/sj.ejcn.1601912.
    Results Reference
    background
    PubMed Identifier
    19083411
    Citation
    Brufau G, Canela MA, Rafecas M. Phytosterols: physiologic and metabolic aspects related to cholesterol-lowering properties. Nutr Res. 2008 Apr;28(4):217-25. doi: 10.1016/j.nutres.2008.02.003.
    Results Reference
    background
    PubMed Identifier
    16522931
    Citation
    Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006 Feb;25(1):41-8. doi: 10.1080/07315724.2006.10719513.
    Results Reference
    background
    PubMed Identifier
    15108714
    Citation
    Jordan S, Griffiths J, Pilon K. Sterol and sterolin-containing products: hematologic adverse reactions. CMAJ. 2004 Apr 13;170(8):1347-8, 1351-2. No abstract available. English, French.
    Results Reference
    background
    PubMed Identifier
    10602355
    Citation
    Hallikainen MA, Sarkkinen ES, Uusitupa MI. Effects of low-fat stanol ester enriched margarines on concentrations of serum carotenoids in subjects with elevated serum cholesterol concentrations. Eur J Clin Nutr. 1999 Dec;53(12):966-9. doi: 10.1038/sj.ejcn.1600882.
    Results Reference
    background
    PubMed Identifier
    11756063
    Citation
    Noakes M, Clifton P, Ntanios F, Shrapnel W, Record I, McInerney J. An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr. 2002 Jan;75(1):79-86. doi: 10.1093/ajcn/75.1.79.
    Results Reference
    background
    PubMed Identifier
    10758959
    Citation
    Rajaratnam RA, Gylling H, Miettinen TA. Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J Am Coll Cardiol. 2000 Apr;35(5):1185-91. doi: 10.1016/s0735-1097(00)00527-1.
    Results Reference
    background
    PubMed Identifier
    16399487
    Citation
    Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):13-21. doi: 10.1016/j.numecd.2005.04.001. Epub 2005 Jul 28.
    Results Reference
    background
    PubMed Identifier
    10190884
    Citation
    Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999 Apr 6;99(13):1733-9. doi: 10.1161/01.cir.99.13.1733.
    Results Reference
    background
    PubMed Identifier
    11472737
    Citation
    Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, Princen HM. Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice. Atherosclerosis. 2001 Aug;157(2):375-81. doi: 10.1016/s0021-9150(00)00750-4.
    Results Reference
    background
    PubMed Identifier
    10801914
    Citation
    Ratnayake WM, L'Abbe MR, Mueller R, Hayward S, Plouffe L, Hollywood R, Trick K. Vegetable oils high in phytosterols make erythrocytes less deformable and shorten the life span of stroke-prone spontaneously hypertensive rats. J Nutr. 2000 May;130(5):1166-78. doi: 10.1093/jn/130.5.1166.
    Results Reference
    background
    PubMed Identifier
    7176832
    Citation
    Child P, Kuksis A. Differential uptake of cholesterol and plant sterols by rat erythrocytes in vitro. Lipids. 1982 Oct;17(10):748-54. doi: 10.1007/BF02534662.
    Results Reference
    background
    PubMed Identifier
    16482072
    Citation
    de Jong A, Plat J, Mensink RP. Plant sterol or stanol consumption does not affect erythrocyte osmotic fragility in patients on statin treatment. Eur J Clin Nutr. 2006 Aug;60(8):985-90. doi: 10.1038/sj.ejcn.1602409. Epub 2006 Feb 15.
    Results Reference
    background
    PubMed Identifier
    12771969
    Citation
    Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr. 2003 May;57(5):681-92. doi: 10.1038/sj.ejcn.1601598.
    Results Reference
    background
    PubMed Identifier
    25541227
    Citation
    Parraga-Martinez I, Lopez-Torres-Hidalgo JD, Del Campo-Del Campo JM, Galdon-Blesa MP, Precioso-Yanez JC, Rabanales-Sotos J, Garcia-Reyes-Ramos M, Andres-Pretel F, Navarro-Bravo B, Lloret-Callejo A. Long-term Effects of Plant Stanols on the Lipid Profile of Patients With Hypercholesterolemia. A Randomized Clinical Trial. Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):665-71. doi: 10.1016/j.rec.2014.07.035. Epub 2014 Dec 23.
    Results Reference
    derived
    PubMed Identifier
    21910898
    Citation
    Parraga I, Lopez-Torres J, Andres F, Navarro B, del Campo JM, Garcia-Reyes M, Galdon MP, Lloret A, Precioso JC, Rabanales J. Effect of plant sterols on the lipid profile of patients with hypercholesterolaemia. Randomised, experimental study. BMC Complement Altern Med. 2011 Sep 12;11:73. doi: 10.1186/1472-6882-11-73.
    Results Reference
    derived

    Learn more about this trial

    Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia

    We'll reach out to this number within 24 hrs